ReviewEJHaem2024

Does Caplacizumab for the management of thrombotic thrombocytopenic purpura increase the risk of relapse, exacerbation, and bleeding? An updated systematic review and meta-analysis based on revised criteria by the International Working Group for thrombotic thrombocytopenic purpura.

Niraj Neupane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.